Selective peroxisome proliferator-activated receptor-α modulator K-877 regulates the expression of ATP-binding cassette transporter A1 in pancreatic beta cells

被引:9
作者
Dong, Tao [1 ]
Lyu, Jingya [1 ]
Imachi, Hitomi [1 ]
Kobayashi, Toshihiro [1 ]
Fukunaga, Kensaku [1 ]
Sato, Seisuke [1 ]
Ibata, Tomohiro [1 ]
Yoshimoto, Takuo [1 ]
Yonezaki, Kazuko [1 ]
Iwama, Hisakazu [2 ]
Zhang, Guoxing [3 ]
Murao, Koji [1 ]
机构
[1] Kagawa Univ, Fac Med, Dept Endocrinol & Metab, 1750-1 Miki Cho, Takamatsu, Kagawa 7610793, Japan
[2] Kagawa Univ, Life Sci Res Ctr, 1750-1 Miki Cho, Takamatsu, Kagawa 7610793, Japan
[3] Soochow Univ, Dept Physiol & Neurosci, Med Coll, 199 Ren Ai Rd,Dushu Lake Campus,Suzhou Ind Pk, Suzhou 215123, Peoples R China
基金
日本学术振兴会;
关键词
PPAR alpha; K-877; Cholesterol; ABCA1; INSULIN-SECRETION; CHOLESTEROL EFFLUX; ABCA1; DISEASE; DYSFUNCTION; INHIBITION; PATHWAY;
D O I
10.1016/j.ejphar.2018.09.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
ATP-binding cassette transporter A1 (ABCA1) protein is a pivotal regulator of cholesterol and phospholipid efflux from cells to high-density lipoprotein (HDL) particles. Pancreatic ABCA1 functions in beta cell cholesterol homeostasis and affects insulin secretion. We investigated the effect of pemafibrate (K-877), a novel selective PPAR alpha modulator (SPPARM alpha), on pancreatic ABCA1 expression. In vivo experiment, mice were divided into four treatment groups, namely, normal food plus placebo, high fat diet (HFD) plus placebo, normal food plus K-877 (0.3 mg/kg/day), or HFD plus K-877 (0.3 mg/kg/day), and treated for eight weeks. The results in vitro experiment indicate that K-877 treatment increased levels of ABCA1 mRNA, as well as protein, subsequently reduced the cellular cholesterol content in INS-1 cells. PPARa specific antagonist GW6471 attenuate K-877 induced ABCA1 expression in INS-1 cells. ABCA1 promoter activity increased with K-877 treatment at concentration 1 mu M and 10 mu M. Glucose-stimulated insulin secretion was ameliorated by K-877 treatment in INS-1 cells and isolated mouse islets. Although the expression of ABCA1 was reduced in mice with HFD treatment, both ABCA1 protein and mRNA levels were increased in mice with K-877 treatment. K-877 treatment improved glucose intolerance induced by HFD in mice. These findings raise the possibility that K-877 may affect insulin secretion by controlling ABCA1 expression in pancreatic beta cells.
引用
收藏
页码:78 / 84
页数:7
相关论文
共 27 条
  • [1] MECHANISMS OF FATTY ACID-INDUCED INHIBITION OF GLUCOSE-UPTAKE
    BODEN, G
    CHEN, XH
    RUIZ, J
    WHITE, JV
    ROSSETTI, L
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (06) : 2438 - 2446
  • [2] Cholesterol in islet dysfunction and type 2 diabetes
    Brunham, Liam R.
    Kruit, Janine K.
    Verchere, C. Bruce
    Hayden, Michael R.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (02) : 403 - 408
  • [3] β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment
    Brunham, Liam R.
    Kruit, Janine K.
    Pape, Terry D.
    Timmins, Jenelle M.
    Reuwer, Anne Q.
    Vasanji, Zainisha
    Marsh, Brad J.
    Rodrigues, Brian
    Johnson, James D.
    Parks, John S.
    Verchere, C. Bruce
    Hayden, Michael R.
    [J]. NATURE MEDICINE, 2007, 13 (03) : 340 - 347
  • [4] Five-hour fatty acid elevation increases muscle lipids and impairs glycogen synthesis in the rat
    Chalkley, SM
    Hettiarachchi, M
    Chisholm, DJ
    Kraegen, EW
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1998, 47 (09): : 1121 - 1126
  • [5] CONTROL OF THE PEROXISOMAL BETA-OXIDATION PATHWAY BY A NOVEL FAMILY OF NUCLEAR HORMONE RECEPTORS
    DREYER, C
    KREY, G
    KELLER, H
    GIVEL, F
    HELFTENBEIN, G
    WAHLI, W
    [J]. CELL, 1992, 68 (05) : 879 - 887
  • [6] Expression of PPARα modifies fatty acid effects on insulin secretion in uncoupling protein-2 knockout mice
    Fatehi-Hassanabad, Zahra
    Chan, Catherine B.
    [J]. NUTRITION & METABOLISM, 2007, 4 (1)
  • [7] Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia
    Fruchart, Jean-Charles
    [J]. CARDIOVASCULAR DIABETOLOGY, 2017, 16
  • [8] A DOUBLE-BLIND CONTROLLED TRIAL OF CLOFIBRATE IN TREATMENT OF DIABETIC RETINOPATHY
    HARROLD, BP
    MARMION, VJ
    GOUGH, KR
    [J]. DIABETES, 1969, 18 (05) : 285 - &
  • [9] Acute (24 h) activation of peroxisome proliferator-activated receptor-α (PPARα) reverses high-fat feeding-induced insulin hypersecretion in vivo and in perifused pancreatic islets
    Holness, MJ
    Smith, ND
    Greenwood, GK
    Sugden, MC
    [J]. JOURNAL OF ENDOCRINOLOGY, 2003, 177 (02) : 197 - 205
  • [10] The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes
    Kahn, SE
    [J]. DIABETOLOGIA, 2003, 46 (01) : 3 - 19